Intravitreal Polypeptide-Polymer Conjugate for Diabetic Retinopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic polypeptide drugs for diabetic retinopathy have a short residence time in the vitreous of the eye, requiring frequent injections and leading to low patient compliance and disease progression.
Innovation Solution
A conjugate comprising a biologically active polypeptide covalently linked to a biocompatible polymer, such as hyaluronic acid, is administered intravitreally, extending the drug's residence time and efficacy by increasing its molecular weight and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If anti-angiogenic polypeptide drugs are administered to treat diabetic retinopathy, then therapeutic effect is achieved, but residence time in vitreous is short requiring frequent injections
Solution Approach 1:
The patent applies composite materials by conjugating anti-angiogenic polypeptide drugs with biocompatible polymers (such as hyaluronic acid, polyethylene glycol, or dextran). This creates a hybrid molecule that combines the therapeutic activity of the polypeptide with the extended circulation and residence properties of the polymer, thereby increasing duration of action in the vitreous and reducing injection frequency
Solution Approach 2:
The patent changes physical parameters by modifying the molecular weight and hydrodynamic radius of the drug through polymer conjugation. The conjugated complex has increased molecular weight and larger hydrodynamic radius compared to the native polypeptide, which slows clearance from the vitreous and extends residence time, thus reducing the frequency of required injections
2Reliability
If frequent injections are required to maintain effective drug levels, then therapeutic efficacy is maintained, but patient compliance decreases
Solution Approach 1:
The patent achieves continuity of useful action by creating a drug-polymer conjugate that maintains effective drug levels in the vitreous for extended periods (weeks to months). The polymer component provides sustained release and prolonged residence time, ensuring continuous therapeutic effect without requiring frequent re-administration, thus improving patient compliance while maintaining efficacy
3Duration of action of moving object
If polypeptide molecular weight is increased through polymer conjugation, then residence time is extended, but drug delivery complexity increases
Solution Approach 1:
The patent uses biocompatible polymers as intermediary carriers that conjugate to the polypeptide drug through well-established chemistry (such as NHS ester coupling to amine groups). These polymer intermediaries provide a standardized platform for attaching therapeutic polypeptides, simplifying the overall conjugation process despite the increased molecular complexity of the final conjugate structure
Data Source
AI summary
The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.